Related by context. All words. (Click for frequent words.) 73 atypical hyperplasia 73 lobular cancer 72 lobular carcinoma 72 nonmelanoma skin cancers 72 endometrial carcinoma 72 bladder cancers 72 prostate pancreatic 72 uterine cancers 72 ovarian cancers 71 breast cancers 71 breast endometrial 71 lobular breast cancer 71 BRCA mutations 71 prostate cancers 71 colorectal cancers 71 invasive carcinoma 71 breast carcinoma 71 endometrial hyperplasia 71 testicular cancers 70 HNSCC 70 ductal breast cancer 70 squamous cell cancers 70 colorectal cancer CRC 70 adenocarcinomas 70 prostate cancer CaP 70 adenomatous polyps 70 BRCA1 mutations 70 invasive ductal 69 bowel cancers 69 colorectal polyps 69 leiomyomas 69 rectal cancers 69 advanced adenomas 69 ductal cancer 69 ovarian lung 69 osteosarcomas 69 cervical lesions 69 adenoma 69 BRCA mutation carriers 69 precursor lesions 68 cancers 68 invasive breast cancer 68 nonmelanoma skin cancer 68 situ LCIS 68 precancerous cervical 68 colorectal adenomas 68 GISTs 68 breast uterine 68 mammographic density 68 pancreatic lung 68 colorectal neoplasms 68 HER2 positive cancers 68 hereditary breast cancer 68 premalignant 68 gastrointestinal cancers 68 gynecologic malignancy 68 pancreatic adenocarcinoma 68 pancreatic prostate 68 ductal carcinomas 67 epithelial ovarian 67 BRCA2 mutations 67 neoplasms 67 colorectal tumors 67 endometrial cancer 67 CIN3 67 gastric cancers 67 ovarian tumors 67 adenomas 67 advanced adenoma 67 carcinomas 67 invasive lobular 67 esophageal cancers 67 thyroid nodules 67 chlamydial infection 67 malignancies 67 benign growths 67 cisplatin resistant 67 pancreatic cancers 67 liver metastasis 67 oophorectomy 67 epithelial tumors 67 nodal metastasis 67 skeletal metastases 67 Uterine fibroids 67 serous ovarian cancer 67 basal cell carcinoma BCC 67 basal cell carcinomas 67 Colon polyps 67 cervical carcinoma 67 atypical ductal hyperplasia 67 colon cancers 67 urothelial carcinoma 67 premalignant lesions 67 testicular tumors 66 colonic polyps 66 operable breast cancer 66 colorectal gastric 66 renal cell carcinomas 66 ovarian cervical 66 gastric adenocarcinoma 66 contralateral breast 66 contralateral breast cancer 66 neoplasia 66 Endometrial cancer 66 ovarian breast 66 colorectal cancer 66 benign breast 66 fibrocystic disease 66 penile cancers 66 progesterone receptor negative 66 epithelial ovarian cancer 66 ovarian carcinoma 66 colorectal neoplasia 66 estrogen receptor negative 66 testicular germ cell 66 bone metastasis 66 ovarian cancer 66 hamartomas 66 neoplasias 65 pulmonary metastases 65 node metastases 65 BRCA1 mutation carriers 65 uterine tumors 65 malignant growths 65 malignancy 65 colorectal carcinoma 65 uterine ovarian 65 seminoma 65 pre cancerous lesions 65 squamous cell carcinomas 65 atypia 65 tumor subtypes 65 prostate carcinoma 65 colorectal adenoma 65 adrenocortical cancer 65 mammary tumors 65 breast ovarian 65 advanced neoplasia 65 Adjuvant chemotherapy 65 squamous cell 65 squamous cell carcinoma SCC 65 premenopausal breast cancer 65 taxane therapy 65 distant metastasis 65 anal cancers 65 curable cancers 65 axillary lymph nodes 65 precancerous tumors 65 squamous cell lung cancer 65 fibrocystic changes 65 ASCUS 65 salpingo oophorectomy 65 basal cell nevus syndrome 65 Squamous cell 65 cervical lymph nodes 65 CIN2 + 65 Prostatitis 65 basal cell cancers 65 breast tumors 65 leukaemias 65 vulvar cancers 65 cervical breast 65 adenocarcinoma 65 oropharyngeal cancer 65 urothelial cancer 65 pleural mesothelioma 65 HER2 positive tumors 65 basal cell skin 64 esophageal adenocarcinoma 64 distant metastases 64 poorer prognosis 64 Cholangiocarcinoma 64 ovarian endometrial 64 tumor histology 64 Adenomas 64 BRCA deficient 64 pre cancerous polyps 64 lung cancers 64 uveal melanoma 64 neuroblastomas 64 ovarian pancreatic 64 neoplastic lesions 64 lymph node removal 64 carcinoid 64 mammary cancers 64 HER2 overexpression 64 metachronous 64 fibroadenomas 64 Metastases 64 endometriosis ovarian cysts 64 prostate adenocarcinoma 64 gastric cardia 64 BRCA2 carriers 64 prostate colon 64 Squamous 64 Papillary 64 choriocarcinoma 64 MYCN amplification 64 PCa 64 specific antigen PSA 64 BRCA carriers 64 cervical intraepithelial neoplasia 64 HGPIN 64 prostate ovarian 64 locoregional recurrence 64 Heavy menstrual bleeding 64 polycystic ovary syndrome PCOS 64 mucinous 64 recurrent ovarian 64 nonmelanoma 64 pancreatic ovarian 64 molecular abnormalities 64 BRCA2 mutation carriers 64 abnormal pap smears 64 bilateral oophorectomy 64 carcinoma 64 thyroid cancers 64 intestinal polyps 64 malignant lesions 64 invasive cervical cancer 64 seminomas 64 rectal cancer 64 ALCL 64 nodular melanoma 64 densest breasts 64 chromosomal abnormalities 64 melanomas 64 differentiated thyroid 64 polycystic ovarian syndrome PCOS 64 colorectal polyp 64 postmenopausal breast cancer 64 Uterine cancer 64 polyp recurrence 64 lobular carcinomas 64 breast carcinomas 64 colon tumors 63 breast pancreatic 63 undergoing radical prostatectomy 63 breast lesions 63 fetal malformations 63 mesotheliomas 63 spontaneous preterm birth 63 KRAS mutations 63 obese postmenopausal 63 Basal cell 63 anal lesions 63 lichen planus 63 gynecologic cancers 63 GnRH agonists 63 lipid abnormalities 63 precancerous condition 63 invasive lobular carcinoma 63 ErbB2 positive 63 chlamydial infections 63 gastrointestinal malignancies 63 hematopoietic cancers 63 Cancers 63 pCR 63 atrophic gastritis 63 prostate abnormalities 63 benign lesions 63 CYT# potent vascular disrupting 63 fallopian tube carcinoma 63 MGUS 63 invasive ductal carcinoma 63 carotid stenosis 63 PSADT 63 mutated BRAF gene 63 cutaneous melanoma 63 denser breasts 63 metastases 63 micrometastases 63 hormonally sensitive 63 abnormal mammograms 63 lung tumors 63 mammographically 63 FGFR2 gene 63 malignant neoplasm 63 spontaneously regress 63 frequently benign tumor 63 hormone receptor negative 63 papillary renal cell carcinoma 63 tumor recurrence 63 anaplastic 63 Basal Cell 63 #.#ng/ml 63 metastatic lesions 63 Recurrences 63 chronic prostatitis 63 nonmetastatic 63 pre cancerous growths 63 HER2 amplified 63 Chlamydia trachomatis infection 63 prostate cancer PCa 63 androgen deprivation 63 benign noncancerous 63 grade gliomas 63 LHRH receptor positive 63 BRCA mutation 63 ovulatory cycles 63 oesophageal adenocarcinoma 63 Malignant Melanoma 63 Testicular cancer 63 TGFBR1 * 6A 63 histological subtype 63 abnormal Pap test 63 Thyroid nodules 63 BRCA2 gene mutation 63 lung pancreatic 63 ADPKD 63 gastric carcinoma 63 adenomatous 63 subclinical hyperthyroidism 63 cervix uteri 63 thyroid carcinoma 63 lymphomas leukemias 63 Fibroid tumors 62 HER2 amplification 62 peritoneal cancer 62 axillary dissection 62 hormone therapy estrogen 62 papillary 62 meningiomas 62 promoter hypermethylation 62 thromboembolisms 62 prophylactic mastectomies 62 gestational diabetes mellitus 62 neuroendocrine carcinoma 62 squamous cell skin 62 renal carcinoma 62 Hurthle cell 62 breast cancer recurrence 62 carotid plaques 62 CIN2 62 PCNSL 62 bladder prostate 62 mutated BRCA1 62 bladder ovarian 62 fibroids endometriosis 62 recurrent miscarriage 62 deCODE BreastCancer TM 62 gallstone disease 62 telomere lengths 62 dysplastic lesions caused 62 systemic scleroderma 62 inherited mutations 62 cervical dysplasia 62 Ovary removal 62 untreated celiac disease 62 estrogen receptor positive 62 preterm delivery 62 renal tumors 62 neuroendocrine tumors 62 carcinoid tumor 62 HER2 negative 62 peritoneal carcinomatosis 62 leiomyoma 62 nasopharyngeal carcinoma 62 colorectum 62 Carcinoma 62 HbF 62 malignant polyps 62 BRCA2 mutation 62 dysplastic nevi 62 tumor subtype 62 hormonally responsive 62 Squamous cell carcinomas 62 spontaneous preterm delivery 62 de ath 62 neoplasm 62 recurrent metastatic 62 precancerous lesions 62 oligodendrogliomas 62 perimenopausal women 62 neuroendocrine cancers 62 prophylactic mastectomy 62 chromosomal aberrations 62 lymph node involvement 62 acute leukemias 62 atypical moles 62 liver metastases 62 colorectal pancreatic 62 lymph node metastases 62 castrate resistant 62 metastatic gastric 62 proximal colon 62 histologic subtype 62 papillomas 62 K ras mutations 62 melanoma 62 pancreatic colon 62 lung adenocarcinoma 62 AAT deficiency 62 Hashimoto thyroiditis 62 fallopian tube cancers 62 hepatocellular cancer 62 BRCA gene mutations 62 Radical prostatectomy 62 endometrial 62 prostate lung 62 paraganglioma 62 GIST tumors 62 estrogen receptor ER 62 Melanomas 62 EGFR mutation 62 SHBG levels 62 invasive ductal carcinomas 62 Genetic variants 62 genital ulcers 62 T1DM 62 basal cell 62 postoperative delirium 62 lung nodules 62 precancers 62 colon polyps 62 p# mutations 62 pulmonary metastasis 62 pre menopausal 62 estrogen progestin therapy 62 pre cancerous 62 precancerous cervical lesions 62 ovulations 62 elevated CRP 62 esophageal tumors 62 gene BRCA2 62 abnormal Pap smears 62 pelvic malignancies 62 pre malignant lesions 62 lung colorectal 62 Adenocarcinoma 62 BRCA gene mutation 62 HER2 positive 61 transitional cell carcinoma 61 hamartoma 61 subclinical hypothyroidism 61 intestinal metaplasia 61 gynecological malignancies 61 SLNB 61 malignant lymphoma 61 germline mutations 61 narcolepsy cataplexy 61 lobular 61 cancerdefine 61 intraepithelial neoplasia 61 bowel polyps 61 breast cancer subtypes 61 urethritis 61 ductal lobular 61 metastatic disease 61 Gliomas 61 Bladder cancer 61 esophagogastric junction 61 ovarian hormones 61 tumors 61 ovarian hyperstimulation syndrome OHSS 61 relapsed ovarian cancer 61 Sjögren syndrome 61 hyperplastic 61 chemopreventive agent 61 chromosomal disorders 61 carcinoid tumors 61 thromboembolic disease 61 bladder tumors 61 premenstrual syndrome PMS 61 adjuvant radiation 61 B7 H3 61 cervical abnormalities 61 breast cancer metastasis 61 hormone receptor positive 61 lung carcinomas 61 esophagus colon 61 Endometrial 61 ductal carcinoma 61 lymph node metastasis 61 venous blood clots 61 histologic subtypes 61 lung metastasis 61 abnormal growths 61 Invasive Breast Cancer 61 colon adenomas 61 HPV# 61 biochemical recurrence 61 adjuvant radiotherapy 61 Breast Cancers 61 diagnostic biomarker 61 vertebral fracture 61 aneuploidies 61 FGFR2 61 Colorectal cancers 61 recurrent VTE 61 unresectable tumors 61 recurrent ovarian cancer 61 squamous cell carcinoma 61 desmoplastic 61 serum prostate 61 KRAS oncogene 61 neurofibromas 61 medically inoperable 61 Polyps 61 thromboembolic events 61 Brain metastases 61 gastric cancer 61 precancerous polyp 61 metastatic kidney 61 lipomas 61 precancer 61 Malignant tumors 61 NMIBC 61 chromosomal anomalies 61 impair fertility 61 extracolonic findings 61 Hodgkin lymphoma HL 61 intravenous bisphosphonates 61 angiosarcoma 61 aerodigestive tract 61 HER2 expression 61 nodal metastases 61 Epidemiologic studies 61 BRCA1 BRCA2 61 preventive mastectomies 61 papillary thyroid carcinoma 61 Basal cell carcinoma 61 GBA mutations 61 Carcinomas 61 colon pancreas 61 paragangliomas 61 oesophageal 61 Carcinoid tumors 61 Clusterin 61 metastatic cancer 61 solar keratosis 61 mTOR inhibitors 61 symptomatic fibroids 61 invasive ductal breast cancer 61 malignant pleural mesothelioma 61 coronary calcification 61 breast cancer 61 HPV infection 61 metastatic prostate 61 transferrin saturation 61 clinically localized prostate 61 endostatin 61 HER2 positive breast cancer 61 faulty BRCA genes 61 elevated triglyceride levels 61 prostate breast 60 TT genotype 60 metastatic bladder 60 preterm deliveries 60 postmenopausal hormone 60 prostate cancer CRPC 60 metastatic prostate cancer 60 MTHFR 60 metastatic colorectal 60 metastatic HER2 positive 60 Erythropoietic therapies may 60 hormonal therapies 60 Metastatic 60 familial pancreatic cancer 60 Pancreatic neuroendocrine tumors 60 cytologic 60 HIV HCV coinfected 60 Non Alcoholic Fatty 60 uterine cervix 60 irregular menstrual cycles 60 incidentalomas 60 malignant neoplasms 60 Leydig cell 60 biochemical relapse 60 preoperative chemotherapy 60 breast ovary 60 axillary node dissection 60 Trichomonas vaginalis 60 Helicobacter pylori infection 60 skin cancers 60 Rectal cancer 60 proliferative diabetic retinopathy 60 EGFR mutations 60 vaginal cancers 60 cancerous enlargement 60 hepatocellular carcinoma HCC 60 malignant melanoma 60 grade cervical intraepithelial 60 Postmenopausal 60 colorectal lung 60 basal cell cancer 60 T1c 60 pre cancerous lesion 60 cancer mCRC 60 astrocytomas 60 thrombotic events 60 colon breast 60 prostate bladder 60 ovarian uterine 60 tibolone 60 cranial irradiation 60 nonproliferative 60 postoperative morbidity 60 polypoid 60 pituitary adenomas 60 parous women 60 keloid scarring 60 squamous cell cancer 60 hypermethylated 60 endometrial tumors 60 noncancerous tumors 60 RET PTC rearrangements 60 placental malaria 60 somatic mutations 60 LRP5 60 pheochromocytoma 60 lymphomas 60 recurrent NSCLC 60 brain lesions 60 hormone refractory 60 epithelial cancers 60 ependymoma 60 upper gastrointestinal bleeding 60 sarcomatoid 60 microbleeds 60 vulvar cancer 60 sarcomas 60 hormone receptor status 60 brain metastases 60 extracapsular extension 60 venous thrombosis 60 pT2 60 breast cancer recurrences 60 perioperative morbidity 60 hyperplastic polyps 60 curative resection 60 postoperative mortality 60 neuroblastoma tumors 60 cranial radiation 60 Ductal carcinoma 60 vulvar intraepithelial neoplasia 60 microvascular disease 60 urine cytology 60 adnexal mass 60 NNRTI resistance 60 PTEN mutations 60 solar keratoses 60 arterial calcification 60 transfusion syndrome 60 thrombophilia 60 colon rectal 60 rs# [001] 60 melanocytic nevi 60 pharyngeal cancer 60 Chlamydia infection 60 prostate carcinomas 60 prostate cancer metastases 60 prognostic indicator 60 atypical nevi 60 Menopausal hormone therapy 60 prolonged QT interval 60 malignant ovarian 60 ovarian malignancy 60 nonsmall cell lung cancer 60 leukemia AML 60 hemorrhagic complications 60 xenograft models 60 endometrial ovarian 60 pleomorphic 60 premalignant lesion 60 Acute lymphoblastic leukemia 60 Seewaldt 60 chronic periodontitis 60 chromosomal rearrangement 60 lobular involution 60 thromboembolism 60 cyclin E 60 subependymal giant cell 60 CC genotype 60 genital tract infections 60 micrometastasis 60 breast cancer genes BRCA1 60 Li Fraumeni 60 Vidaza ® 60 malignant transformation 60 Leukemias 60 Renal Cell Carcinoma RCC 60 normal karyotype 60 sentinel nodes 60 cervical neoplasia 60 GBM tumors 60 Glioblastoma Multiforme GBM 60 ALK mutations 60 pre cancerous cells 60 thrombotic complications 60 Benign prostatic hyperplasia BPH 60 benign nodules 60 cerebral microbleeds 60 overexpress HER2 60 nonalcoholic steatohepatitis NASH 60 prostate specific 60 benign proliferative breast 60 antigen PSA 60 breast tenderness 60 hepatocellular carcinoma 60 HBeAg negative 60 chromosomal anomaly 60 deCODE BreastCancer 60 metastatic adenocarcinoma 60 CMV infection 60 prostate tumors 60 genital herpes infections 60 lung ovary 60 Glioblastomas 60 fibrocystic 60 hypovitaminosis D 60 PARP inhibition 60 vestibular schwannomas 60 hormone deprivation 60 micro calcifications 60 BRCA1 mutation 60 Hematologic 60 hereditary predisposition 60 metastatic pancreatic 60 colon rectum breast 60 nasopharyngeal cancer 60 bronchopulmonary dysplasia 60 dentinal hypersensitivity 59 situ DCIS 59 myeloproliferative diseases 59 cell carcinoma 59 abnormal vaginal bleeding 59 HER2 positive metastatic breast 59 osteoporotic fractures 59 breast colon 59 Folic acid supplements 59 invasive carcinomas 59 androgen ablation 59 neoadjuvant therapy 59 neoadjuvant chemotherapy 59 pancreatic neuroendocrine tumors 59 lignan intake 59 ABCB1 59 atherosclerotic lesions 59 Stomach cancer 59 metastatic neuroendocrine tumors 59 gynecological cancers 59 pheochromocytomas 59 intraductal 59 BRCA2 gene mutations 59 methylation markers 59 EGFR mutant 59 imatinib Gleevec 59 subclinical atherosclerosis 59 fetal chromosomal 59 BRAF mutations 59 overt hepatic encephalopathy HE 59 Folate deficiency 59 benign uterine 59 mtDNA mutations 59 atypical lobular hyperplasia 59 adenomatous polyp 59 distal colon cancer 59 metastatic malignant 59 hypertrophic scars 59 glandular tissue 59 Cytogenetic 59 commonly mutated genes 59 Ovarian cysts 59 perioperative complications 59 orchiectomy 59 C. trachomatis 59 papillary carcinoma 59 abnormal cervical 59 p# mutation 59 medullary thyroid cancer 59 resistant hormone refractory 59 pancreatic bladder 59 colorectal cancer incidence 59 ovarian colorectal 59 ductal 59 neurologic complications 59 ductal adenocarcinoma 59 undergone radical prostatectomy 59 BRAF V#E 59 colon rectum 59 sentinel node biopsy 59 penetrance 59 abnormal pap tests 59 nonhereditary 59 metastatic lymph nodes 59 spontaneous regression 59 surgical biopsies 59 singleton pregnancy 59 Digital Mammographic Imaging 59 colorectal prostate 59 papillary thyroid cancer 59 hirsutism 59 human papillomaviruses HPV 59 congenital anomalies 59 genetic syndromes 59 anovulatory infertility 59 Fibroids 59 polyps growths 59 relapsed MM 59 rebleeding 59 EUS FNA 59 liver fibrosis 59 antiestrogen 59 epigenetic changes 59 DCIS ductal carcinoma 59 antiangiogenic therapy 59 leukemia ALL 59 Gastric cancer 59 endometrial kidney 59 Anaplastic 59 CaP 59 oesophageal cancer 59 malignant prostate 59 thyroid hormone levels 59 postmenopausal hormones 59 debulking surgery 59 catheter angiography 59 pituitary tumors 59 benign prostatic hypertrophy 59 KRAS mutation 59 recurrent UTI 59 lymphoma subtypes 59 androgen deficiency 59 gestational hypertension 59 flutamide 59 grade glioma 59 genomic alterations 59 immunocompetent 59 hepatocellular carcinomas 59 castration resistant 59 Anthracycline 59 cervical uterine 59 recurrent venous thromboembolism 59 pelvic inflammatory disease 59 adjuvant therapies 59 clinicopathologic 59 primary ovarian insufficiency 59 familial adenomatous polyposis 59 colorectal adenocarcinoma 59 bile duct cancers 59 cervical lymph node 59 detecting precancerous 59 subclinical disease 59 ovary uterus 59 postmenopausal hormone replacement 59 liver scarring 59 atopic diseases 59 abnormal mammogram 59 KRAS status 59 congenital abnormalities 59 HPV infections 59 postoperative atrial fibrillation 59 EGFR inhibitors 59 cell carcinomas 59 diffuse gastric 59 lung esophageal 59 BRAF mutation 59 JAK mutations 59 B Cell Lymphoma 59 cystic lesions 59 TP# mutations 59 monogenic 59 neoadjuvant treatment 59 hormonal therapy 59 cTnT 59 abnormal cytology 59 tumors GIST 59 gonococcal infection 59 recurrent miscarriages 59 leiomyosarcoma 59 resectable 59 carcinoma HNSCC 59 gemcitabine Gemzar 59 axillary nodes 59 abnormal Pap smear 59 gastrointestinal stromal tumors GISTs 59 Estrogens 59 endocrine tumors 59 cancerous breast 59 pre eclamptic 59 Hepatocellular Carcinoma HCC 59 advanced HER2 positive 59 oral squamous cell 59 CYP#D# inhibitor 59 DCIS 59 prognostic indicators 59 infantile hemangiomas 59 vaginal lesions 59 hereditary nonpolyposis colorectal cancer 59 Hemangiomas 59 malignant tumors 59 Li Fraumeni syndrome 59 acute myelogenous leukemia AML 59 clinically insignificant 59 T1a 59 esophageal squamous cell carcinoma 59 gynecologic cancer 59 etiologic 59 HER2 positive breast 59 VUR 59 endocrine therapies 59 adenoma recurrence 59 microdeletions 59 non squamous NSCLC 59 SPINK1 59 thyroid dysfunction 59 pathogenic mutations 59 bacteriuria 59 colorectal carcinomas 59 chorioamnionitis 59 recurrent glioblastoma multiforme 59 cervical vaginal 59 malignant brain 59 neoplasia PIN 59 Candida infection 59 KRAS mutations occur 59 mosaicism 59 nonpregnant women 59 glial tumors 59 polycystic ovary syndrome 59 Tumours 59 sCJD 59 underwent resection 59 apolipoprotein E gene 59 Acute myeloid leukemia 59 TCF#L# gene 58 ependymomas 58 candidemia 58 sonographic findings 58 soft tissue sarcomas 58 Malignancies 58 CMV disease 58 obstructive coronary 58 radiosensitive 58 Thyroid cancer 58 uterus womb 58 GSTT1 58 CVD mortality 58 Ductal Carcinoma 58 benign polyps 58 DVT PE 58 genetic polymorphisms 58 Sentinel node biopsy 58 beta carotene supplementation 58 localized renal 58 antiproliferative effects 58 lung adenocarcinomas 58 AUDs 58 missense mutations 58 EBRT 58 endometrial biopsy 58 cholangiocarcinoma 58 fibroma 58 CP CPPS 58 hypermethylation 58 Anal cancer 58 myelofibrosis polycythemia vera 58 myomas 58 AstraZeneca Arimidex 58 allogeneic HSCT 58 herpes simplex encephalitis 58 papilloma 58 ovarian colon 58 #F FDG PET 58 gestational diabetes mellitus GDM 58 androgen suppression therapy 58 medulloblastomas 58 PAOD 58 lung lesions 58 Inhibin B 58 thyrotropin levels 58 gonococcal infections 58 mucosal lesions 58 Epstein Barr virus EBV 58 core needle biopsies 58 aneuploid cells 58 proliferative retinopathy 58 colorectal breast 58 endometrial thickness 58 locoregional 58 asymptomatic PAD 58 cirrhosis liver failure 58 PSA velocity 58 Venous thromboembolism 58 genes BRCA1 58 superficial bladder cancer 58 HER2 + 58 Toxicities 58 supratentorial 58 NSCLC tumors 58 Prognostic factors 58 laryngeal cancer 58 LHRH analogues 58 mutated K ras 58 receptor tyrosine kinase inhibitor 58 prostate carcinogenesis 58 dysplastic lesions 58 APOL1